Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma

Cancer

Volumn 94, Issue 2, 2002, Pages 331-343

  Shojamanesh, Homayoun ^a   Gibril, Fathia ^a   Louie, Adeline ^b   Ojeaburu, Jeremiah V ^a   Bashir, Showkat ^a   Abou Saif, Alaa ^a   Jensen, Robert T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Gastrinoma; Islet tumor; Pancreatic endocrine tumor; Somatostatin analogue; Zollinger Ellison syndrome (ZES)

Indexed keywords

OCTREOTIDE;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; GASTRINOMA; HUMAN; METASTASIS; NAUSEA; PRIORITY JOURNAL; TREATMENT INDICATION; TUMOR VOLUME; VOMITING; ZOLLINGER ELLISON SYNDROME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GASTRINOMA; GASTRINS; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OCTREOTIDE; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTORS, SOMATOSTATIN; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 0037080438     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10195     Document Type: Article

References (70)

1. Natural history of neuroendocrine enteropancreatic tumors
2. Natural history of digestive endocrine tumors
3. Benign and malignant gastrinoma
4. Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome
5. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area
6. Gastrinoma
7. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: A prospective long-term study
8. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns
9. Recent advances in diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract
10. Pancreatic endocrine tumors
11. Systemic chemotherapy for endocrine tumors of the pancreas: Recent advances
12. Prospective study of chemotherapy in patients with metastatic gastrinoma
13. An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma
14. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors
15. Streptozotocin-doxorubicin, streptozotocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma
16. Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma
17. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients
18. Peptide therapy. Recent advances in the use of somatostatin and other peptide receptor agonists and antagonists
19. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours
20. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors
21. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: A prospective study in 39 patients
22. Treatment of neuroendocrine GEP tumours with somatostatin analogues: A review
23. The significance of somatostatin analogues in the antiproliferative treatment of carcinomas
24. Endocrine tumors of the pancreas
25. Carcinoid tumors and the carcinoid syndrome
26. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours
27. Survival factors in patients with endocrine liver metastases
28. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: The best approach
29. Zollinger-Ellison syndrome: Clinical presentation in 261 patients
30. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1
31. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome: A prospective study
32. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome
33. Gastric secretion in Zollinger-Ellison syndrome: Correlation with clinical expression, tumor extent and role in diagnosis - A prospective NIH study of 235 patients and review of the literature in 984 cases
34. Surgery to cure the Zollinger-Ellison syndrome
35. Bone metastases in patients with gastrinomas: A prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management
36. Metastatic gastrinomas: Localization with selective arterial injection of secretin
37. Distinguishing small hepatic hemangiomas from vascular liver metastases in patients with gastrinoma: Use of a somatostatin-receptor scintigraphic agent
38. Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: A prospective study
39. Zollinger-Ellison syndrome
40. Carcinoid and pancreatic endocrine tumors: Recent advances in molecular pathogenesis, localization, and treatment
41. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors
42. Multiple endocrine neoplasia
43. Chemotherapy in the treatment of neuroendocrine malignant tumors
44. Intravenous chemotherapy with streptozotocin and 5 fluorouracil for hepatic metastases of Zollinger-Ellison syndrome. A prospective multicenter study in 21 patients
45. Somatostatin receptor-dependent growth inhibition of liver metastases by octreotide
46. Slow-release lanreotide treatment in endocrine gastrointestinal tumors
47. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects
48. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors
49. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours
50. Endocrine neoplasms of the pancreas
51. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide
52. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors
53. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors
54. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms
55. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2
56. Treatment of type II gastric carcinoid tumors with somatostatin analogues
57. Treatment of the malignant carcinoid syndrome (MCS) with a long acting somatostatin analogue (SMS 201-995): Preliminary evidence that more is not better
58. Use of the long-acting somatostatin analog, SMS 201-995 in patients with pancreatic islet cell tumors
59. Somatostatin and somatostatin analogue (SMS 201- 995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut
60. Use of octreotide in the treatment of digestive neuroendocrine tumours. Seven year experience in 20 cases including 9 cases of metastatic midgut carcinoid and 5 cases of metastatic gastrinoma
61. Characterization of the in vivo and in vitro inhibition of gastrin secretion from gastrinoma by a somatostatin analogue (SMS 201-995)
62. Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue
63. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlook
64. Pancreatic endocrine tumors
65. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors
66. Octreotide
67. Mechanisms of antineoplastic action of somatostatin analogs
68. Antiproliferative effect of somatostatin and analogs
69. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs
70. Somatostatin analogs: Angiogenesis inhibitors with novel mechanisms of action